Myeloperoxidase cytochemical negativity: an unexpected but intrinsic property of blasts of all phases of chronic myeloid leukemia

Anand, Mona; Ghara, Niharendu; Kumar, Rajive; Singh, Sarika; Sengar, Manju; Panikar, Nirupama; Raina, Vinod; Sharma, Atul
December 2005
Annals of Hematology;Dec2005, Vol. 84 Issue 12, p767
Academic Journal
Myeloperoxidase (MPO) cytochemical activity, recognized as a very important hallmark of myeloblasts, is generally negative in chronic myeloid leukemia (CML) blast crisis (BC). Because this finding is unexpected, being not in keeping with the myeloproliferative nature of CML, we tried to ascertain if MPO cytochemical negativity could be an intrinsic property of blasts of CML and hence present in the preblastic phases as well. Myeloperoxidase cytochemistry of peripheral blood blasts in 161 cases of CML, including 103 in chronic phase (CP) and 29 each in accelerated phase (AP) and BC, was assessed and compared with that of 30 cases of acute myeloid leukemia, AML-M2. Blasts of 97 (94.2%) of 103 cases of CP, 28 (96.6%) of 29 cases of AP, and 22 (75.9%) of 29 cases of BC were negative for MPO (<3% MPO-positive blasts). Compared with the strong MPO positivity, both in terms of intensity and proportion, in the AML-M2 cases, the positivity in the CML cases was generally weak and was seen in a small number of blasts (5–15%), except in one case of BC with 20% positive blasts. Absence or, at times, weak MPO cytochemical activity is an intrinsic property of blasts of all phases of CML, and use of the term myeloblast in CML should be understood to refer to a cell with this property. This also explains why MPO cytochemistry, despite its high reputation as a myeloid-lineage marker, generally does not help in CML BC. CML BC should therefore be considered as a possible diagnosis along with acute lymphoblastic leukemia, AML-M0, AML-M7, etc., in the setting of MPO-negative blasts. Similarity between MPO expression pattern in CML, i.e., negative in blasts and positive in the more mature cells, and that during maturation of normal myeloid series of cells shows the deranged myelopoiesis of CML to be undisturbed at least with respect to MPO expression. There is need for a more comprehensive study of blasts of preblastic phases.


Related Articles

  • Differential stability of control gene and fusion gene transcripts over time may hamper accurate quantification of minimal residual disease - a study within the Europe Against Cancer Program. van der Velden, V. H. J; Boeckx, N.; Gonzalez, M.; Malec, M.; Barbany, G.; Lion, T.; Gottardi, E.; Pallisgaard, N.; Beillard, E.; Hop, W. C. J.; Hoogeveen, P. G.; Gabert, J.; van Dongen, J. J. M // Leukemia (08876924);Apr2004, Vol. 18 Issue 4, p884 

    During the last decade, several studies have shown that quantification of minimal residual disease (MRD) provides prognostic information that can be used for treatment decisions in individual patients. In acute lymphoblastic leukemia, MRD information obtained at early time points during therapy...

  • Granulocytic sarcoma in children. Porto, L.; Kieslich, M.; Schwabe, D.; Zanella, F.E.; Lanfermann, H. // Neuroradiology;May2004, Vol. 46 Issue 5, p374 

    We report three children with leukaemia (two acute myeloid and one acute lymphoblastic) and granulocytic sarcoma in the skull, orbit and sinuses. Lesions in these sites in children, with or without bone changes, are suggestive of systemic diseases such as lymphoproliferative conditions. Although...

  • Impairment in functional status and survival in patients with acute myeloid leukaemia. Wedding, Ulrich; Röhrig, Bernd; Klippstein, Almuth; Fricke, Hans-Joerg; Sayer, Herbert; Höffken, Klaus // Journal of Cancer Research & Clinical Oncology;Oct2006, Vol. 132 Issue 10, p665 

    Acute myeloid leukaemia (AML) is mainly affecting elderly patients. Elderly patients are increasingly affected by impairment of functional status (FS). FS is of prognostic relevance for survival in different tumours. Data for patients with AML are rare. Within a prospective trial we recruited...

  • Dasatinib: In Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Keam, Susan J. // BioDrugs;2008, Vol. 22 Issue 1, p59 

    ▴ Dasatinib is a small-molecule inhibitor of multiple tyrosine kinases, including BCR-ABL, SRC, c-KIT, ephrin A receptor and platelet-derived growth factor-β receptor kinases, at nanomolar concentrations. In vitro, dasatinib is 325-fold more potent than imatinib against...

  • Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL1. Schiffer, C A; Hehlmann, R; Larson, R // Leukemia (08876924);Apr2003, Vol. 17 Issue 4, p691 

    Chronic myeloid leukaemia (CML) is a malignant disease of the bone marrow characterised by the presence of the Philadelphia (Ph) chromosome. About 20% of acute lymphoblastic leukaemia (ALL) patients also show this genetic abnormality. A new drug, imatinib (Glivec®, Novartis Pharma AG, Basel,...

  • Expression of c-Fes Protein Isoforms Correlates with Differentiation in Myeloid Leukemias. Carlson, Anne; Berkowitz, Jeanne Mcadara; Browning, Damaris; Slamon, Dennis J.; Gasson, Judith C.; Yates, Karen E. // DNA & Cell Biology;May2005, Vol. 24 Issue 5, p311 

    The cellular fes gene encodes a 93-kilodalton protein-tyrosine kinase (p93) that is expressed in both normal and neoplastic myeloid cells. Increased c-Fes expression is associated with differentiation in normal myeloid cells and cell lines. Our hypothesis was that primary leukemia cells would...

  • amsacrine.  // Royal Society of Medicine: Medicines;2002, p56 

    The article provides information on amsacrine, a cytotoxic anticancer drug which is used specifically in the treatment of acute myeloid leukaemia. Administration is by intravenous infusion. Side effects include heartbeat irregularities.

  • Amsidine.  // Royal Society of Medicine: Medicines;2002, p56 

    The article provides information on Amsidine, a proprietary, prescription-only preparation of the anticancer drug amsacrine. It can be used to treat acute myeloid leukaemia, and is available in a form for intravenous infusion.

  • Disseminated scabies evolving in a patient undergoing induction chemotherapy for acute myeloblastic leukaemia. Trendelenburg, M.; Büchner, S.; Passweg, J.; Rätz Bravo, A.; Gratwohl, A. // Annals of Hematology;Feb2001, Vol. 80 Issue 2, p116 

    We report on a 34-year-old refugee from the Balkans presenting with a generalized papular rash during induction chemotherapy for acute myeloblastic leukaemia (AML M4eo). This rash appeared on day 5 of the chemotherapy and was diagnosed as disseminated scabies. It was successfully treated with a...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics